Bionutrics, Inc. Launches A Vitamin-E Replacement.

Business & Health Editors

PHOENIX--(BUSINESS WIRE)--March 20, 2001

Bionutrics, Inc., (Nasdaq: BNRX) announced today that it is launching a new tocotrienol-based cardiovascular health product under the brand name of "Vitenol E(R) 20/20 -- For Heart and Health".

The new patent-protected product is a rice bran extract containing all eight standard isomers of vitamin E (including tocotrienols) together with phytosterols. Vitenol- E(R) 20/20 has been shown to be up to 20 times more effective than standard vitamin E (alpha-tocopherol) as an antioxidant. The United States market for vitamin E approaches $1 billion.

Vitenol- E(R) 20/20 is supplied to Bionutrics by ACH Food Companies, Inc. (a subsidiary of Associated British Foods plc of London, England), and is manufactured at InCon Processing, LLC of Batavia, IL. InCon Processing is a food ingredient manufacturing and chemical separation company jointly owned by Bionutrics and ACH Food Companies.

Howard Schneider, Ph.D., President of LipoGenics, Inc. (Bionutrics' wholly owned R&D subsidiary), stated that "the importance of alpha-tocopherol vitamin E for cardiovascular health is well-recognized within the health and medical communities. Unfortunately, however, alpha-tocopherol vitamin E is not a highly potent antioxidant nor does it exhibit many benefits of other vitamin E isomers. Alpha-tocopherol vitamin E, therefore, requires relatively high doses to provide its limited beneficial health effects. Our proprietary Vitenol- E(R) 20/20 is formulated with all eight standard isomers of vitamin E, including highly active tocotrienols. This "mixed isomer" composition provides coverage of activities associated with many forms of vitamin E. Also containing high levels of rice bran phytosterols, Vitenol- E(R) 20/20 is unique in its composition and activity, with a significant advantage compared to other vitamin E products.

Bionutrics Health Products' Vice President of Sales and Marketing, Richard Mott, further commented "The timing of this rollout is great for us. Last month we launched our new cholesterol-lowering product CARDIO-CIN(TM) and are receiving good responses from the trade. Vitenol- E(R)20/20, positioned as our second new cardiovascular dietary supplement product, complements CARDIO-CIN(TM) and gives us greater strength in a very important category. Vitenol- E(R)20/20, with its patent protection and superior activity, provides an important "point-of difference" to which the trade is highly responsive. Having ACH Food Companies as our manufacturing partner and processing through InCon provides quality and economic advantages for our customers and us. We have great expectations for Vitenol- E(R)20/20."

Bionutrics is a biopharmaceutical company founded to discover and develop novel biologically active compounds derived from natural sources. Natural, biologically active compounds have potential applications as functional nutrition ingredients as well as ethical drugs. Bionutrics is presently developing proprietary functional nutrition ingredients and pharmaceutical products and intends to market these products through strategic alliances.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This release contains forward looking statements that are subject to the risks and uncertainties, including, but not limited to, the impact of competitive products and pricing, product demand and market acceptance, new product development, future research, reliance on key strategic alliances, availability of raw materials, the regulatory environment and governmental approval processes, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.